Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.30 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.30 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24743661 | 0.79 | ADRB2 (0.36) | ADRB2ADRB1ADRB3ADRA2AADRA2B | |
| SCHEMBL14951743 | 0.78 | GABRA1 (0.44) | ADRB2ADRB1ADRB3ADRA2AADRA2B | |
| SCHEMBL24133915 | 0.69 | GABRA1 (0.50) | GABRA1GABRB2MEP1AMEP1B | |
| SCHEMBL24724632 | 0.68 | TSHR (0.47) | ADRB2ADRB1ADRB3ADRA2AADRA2B | |
| SCHEMBL24761803 | 0.68 | HMGCR (0.31) | — | |
| SCHEMBL22924942 | 0.67 | ADRB2 (0.43) | ADRB2ADRB1ADRB3ADRA2BGABRA1 | |
| SCHEMBL12891864 | 0.67 | CES2 (0.42) | ADRB2ADRB1ADRB3CES2CES1 | |
| SCHEMBL30567471 | 0.67 | RORC (0.42) | GABRA1GABRB2 | |
| SCHEMBL2737293 | 0.66 | GABRA1 (0.50) | ADRB2ADRB1ADRB3ADRA2AADRA2B | |
| SCHEMBL16117022 | 0.66 | TSHR (0.44) | ADRB2ADRB1ADRB3ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447452-B2 | Agonists of peroxisome proliferator-activated receptor alpha and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210024469-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2021-01-28 | — | — | US | disclosed |
| WO-2019178439-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024469-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND METHODS OF USE | PPARG, PPARA, PPARD | ADRB2 86/4885ADRB1 30/4885ADRB3 68/4885 |
| US-11447452-B2 | Agonists of peroxisome proliferator-activated receptor alpha and methods of use | PPARG, PPARA, PPARD | ADRB2 86/4885ADRB1 30/4885ADRB3 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.